Affiliation:
1. Department of Medicine, Michael Reese Hospital and Medical Center, affiliated with the Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60616
Abstract
Eighty-seven isolates of
Pseudomonas, Enterobacteriaceae
, and
Staphylococcus
, chosen because of their resistance to other aminoglycosides, were tested for susceptibility to 5-episisomicin. Tests were performed in Mueller-Hinton agar and also, with 38 of these isolates, in Mueller-Hinton broth. Of
Enterobacteriaceae
, 85 and 95.5% were inhibited by 5 and 10 μg of 5-episisomicin per ml, respectively. Amikacin inhibited 74 and 91% of the strains at 10 and 20 μg/ml, respectively. Fifty-four percent of
P. aeruginosa
were inhibited by 5-episisomicin and amikacin. Eighty-three percent of
S. aureus
were inhibited by netilmicin and amikacin, whereas only 50% were inhibited by 5-episisomicin. Isolates resistant to 5-episisomicin were most often resistant to the other aminoglycosides and occurred in gram-negative bacilli that did not carry aminoglycoside-modifying enzymes. Five of 23 isolates that carried a 6′-
N
-acetyltransferase (AAC-6′) and one of two that carried an aminoglycoside 3-acetyltransferase were resistant to and acetylate 5-episisomicin. Strains carrying other aminoglycoside-modifying enzymes were inhibited by 5-episisomicin. Thus, 5-episisomicin is a promising aminoglycoside not attacked by most aminoglycoside-modifying enzymes. Resistance will probably most often be based upon nonenzymatic mechanisms which will also affect other aminoglycosides.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献